Showing 3681-3690 of 3978 results for "".
- Indoor Tanning Among High Schoolers Linked to Other Risky Behaviorhttps://practicaldermatology.com/news/20140227-indoor_tanning_among_high_schoolers_linked_to_other_risky_behavior/2459329/A national survey of high school students found that indoor tanning is a common practice, particularly among female, older and non-Hispanic white students, and is associated with several other risky health-related behaviors, according to a study by Gery P. Guy Jr., PhD, MPH of t
- Video Intervention May Increase Skin Cancer Diagnosis in Older Menhttps://practicaldermatology.com/news/20140224-video_intervention_may_increase_skin_cancer_diagnosis_in_older_men/2459334/Showing men a video on skin self-examination and skin awareness may help to increase the number of patients who receive whole-body clinical skin examinations (CSEs) from their physicians, which could increase skin cancer diagnosis in older men, according to a study by Monika Jan
- Support Camp Discovery: Follow Us on Twitterhttps://practicaldermatology.com/news/20140130-support_camp_discovery_follow_us_on_twitter/2459354/Practical Dermatology® is excited to announce that we'll donate 20 cents for every new Twitter follower from Jan. 31, 2014 through March 14, 2014* to Camp Discovery. Simply follow @Practical_Derm on Twitte
- Curt Cole Wins "Best Presentation of the Day" and Lifetime Achievement Awards at Winter Clinical Dermatology Conferencehttps://practicaldermatology.com/news/20140128-curt_cole_wins_best_presentation_of_the_day_and_lifetime_achievement_awards_at_winter_clinical_dermatology_conference/2459357/"Beyond Broad Spectrum: Critical Concepts in a Post-Monograph World " - a podium presentation by photobiologist and industry veteran Curtis Cole, Ph.D, - was voted "Best Presentation of the Day," Tuesday, January 21 at the Winter Clinical Dermatology Conference. Given the broad scope of topics
- AAD Responds to New York Timeshttps://practicaldermatology.com/news/20140127-aad_sumbits_letter_to_the_editor_to_new_york_times/2459358/In response to The New York Times article “Patients' Costs Skyrocket; Specialists' Incomes Soar” (“Paying Till It Hurts” series, Jan. 19, 2014), the American Academy of De
- DERM: The Dermatology Essential Resource Meeting Announcedhttps://practicaldermatology.com/news/20140122-derm_the_dermatology_essential_resource_meeting_announced/2459364/DERM 2014: The Dermatology Essential Resource Meeting will be held July 24-27 at the Encore in Las Vegas. This new, accredited conference focuses exclusively on clinically relevant and practical educational needs of NPs and PAs in dermatology, according t
- Cutera Appoints Scott Ashworth as Executive Vice President of Global Saleshttps://practicaldermatology.com/news/20131230-cutera_appoints_scott_ashworth_as_executive_vice_president_of_global_sales/2459385/Scott Ashworth recently joined Cutera as Executive Vice President of Global Sales. He brings twenty-five years of experience in building and leading global sales and marketing teams focused on commercialization of products, establishing distributio
- Acneiform Eruptions Examined in New Bookhttps://practicaldermatology.com/news/20131223-acneiform_eruptions_examined_in_new_book/2459387/A new book that addresses the differential diagnosis of acne vulgaris and treatment of acne-like condition is now available through Springer. Acneiform Eruptions in Dermatology, edited by Practical Dermatology Board Member Joshua A. Zeichner, MD, offers expert guidance on acne and syst
- Valeant Pharmaceuticals Announces Appointment of Dr. Ari Kellen to Executive Management Teamhttps://practicaldermatology.com/news/20131125-valeant_pharmaceuticals_announces_appointment_of_dr_ari_kellen_to_executive_management_team/2459405/Valeant Pharmaceuticals International, Inc. announced that Dr. Ari Kellen has been named to Valeant's Executive Management Team and will assume the role of Executive Vice President/Company Group Chairman, effective January 1,
- Valeant's Antifungal Agent Luzu Wins FDA Approvalhttps://practicaldermatology.com/news/20131115-valeants_antifungal_luzu_wins_fda_approval/2459414/The FDA has approved Luzu® (luliconazole, Valeant) Cream, 1% for the topical treatment of athlete's foot (interdigital tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis), caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and olde